EDECRIN by Bausch + Lomb is clinical pharmacology pharmacokinetics and metabolism edecrin acts on the ascending limb of the loop of henle and on the proximal and distal tubules. Approved for edema. First approved in 1967.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
EDECRIN (ethacrynic acid) is a loop diuretic that acts on the ascending limb of the loop of Henle and renal tubules to promote sodium, chloride, and water excretion. It is indicated for edema associated with conditions such as congestive heart failure, renal disease, and hepatic cirrhosis. The drug works by inhibiting electrolyte reabsorption in the nephron, producing diuresis several times greater than thiazide diuretics.
Product is in late-stage lifecycle with minimal Part D claims and approaching loss of exclusivity, indicating a mature/declining franchise with limited commercial expansion.
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism EDECRIN acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several…
Worked on EDECRIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moEDECRIN has zero linked job openings, reflecting its mature LOE-approaching lifecycle and minimal commercial resource allocation. Employment opportunities on this product are extremely limited and typically maintenance-focused rather than growth-oriented.